cardiovascular-agents and Hyperaldosteronism

cardiovascular-agents has been researched along with Hyperaldosteronism* in 4 studies

Reviews

1 review(s) available for cardiovascular-agents and Hyperaldosteronism

ArticleYear
Aldosterone and cardiovascular disease.
    Current problems in cardiology, 2009, Volume: 34, Issue:2

    Aldosterone is an adrenal hormone that regulates sodium, fluid, and potassium balance. Jerome Conn first described the syndrome of autonomous and excessive aldosterone secretion or "primary aldosteronism." Contrary to the historical belief, recent studies indicate that primary aldosteronism is a common cause of hypertension with a prevalence of 5-10% among general hypertensive patients. Various animal models have demonstrated that aldosterone in association with a high salt diet results in target-organ inflammation and fibrosis. Similarly, cross-sectional and observational human studies have demonstrated the association of aldosterone with development and severity of hypertension, congestive heart failure, coronary artery disease, chronic kidney disease, and metabolic syndrome. Several interventional studies have also demonstrated the beneficial effects of mineralocorticoid receptor antagonists in these disease processes, particularly hypertension, heart failure, and post myocardial infarction, further supporting the role of aldosterone in their pathogenesis. We review the role of aldosterone in these various cardiovascular disease processes along with potential mechanisms and treatment.

    Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Treatment Outcome

2009

Other Studies

3 other study(ies) available for cardiovascular-agents and Hyperaldosteronism

ArticleYear
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2015, Volume: 16, Issue:6

    Refractory hyperaldosteronism is frequently observed in heart failure patients on up-to-date treatment, and holds prognostic value. Our aim was to identify which factors, either genetic or nongenetic, are associated with refractory hyperaldosteronism.. We enrolled 109 consecutive patients with left ventricular systolic dysfunction [left ventricular ejection fraction (LVEF) 32 ± 10%; 86% males; age 65 ± 13 years (mean ± standard deviation)] on optimized adrenergic and renin-angiotensin-aldosterone system (RAAS) antagonism, undergoing clinical and neuroendocrine characterization, and genotyping for six polymorphisms in key RAAS-regulating genes [angiotensinogen (AGT M235T), angiotensin-converting enzyme (ACE-240A>T and I/D), angiotensin II type I receptor (AGTR1 1166A>C), aldosterone synthase (CYP11B2-344C>T) and renin (REN rs7539596)].. Patients with refractory hyperaldosteronism (n = 41, 38%, with plasma concentration >180 ng/l, URL, median 283 ng/l, interquartile range 218-433), when compared with those without (106 ng/l, 74-144; P < 0.001), were not different either for treatment or LVEF, while presented with different AGT M235T genotype distribution (P = 0.047). After adjustment for several humoral, instrumental, functional and therapeutical variables, only plasma renin activity (PRA) (P < 0.001) and potassium (P = 0.027) were independently associated with refractory hyperaldosteronism. Among polymorphisms, only AGT M235T (P = 0.038) was associated with refractory hyperaldosteronism, after adjustment for nongenetic variables.. In conclusion, refractory hyperaldosteronism in heart failure may be influenced by AGT M235T polymorphism, among RAAS candidate genes, and by PRA, which may represent, respectively, a constitutive (genotype dependent) and a nongenetic (phenotype-dependent) trigger for aldosterone elevation.

    Topics: Aged; Angiotensinogen; Biomarkers; Cardiovascular Agents; Female; Follow-Up Studies; Gene Frequency; Genetic Predisposition to Disease; Heart Failure; Humans; Hyperaldosteronism; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Renin; Renin-Angiotensin System

2015
Aldosterone and Cardiovascular Disease. Foreword.
    Current problems in cardiology, 2009, Volume: 34, Issue:2

    Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists

2009
Scientists probe aldosterone's role in hypertension and heart disease.
    JAMA, 2004, Dec-08, Volume: 292, Issue:22

    Topics: Aldosterone; Cardiovascular Agents; Cardiovascular Physiological Phenomena; Heart Diseases; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists

2004